Drug intelligence / Profile preview

Zytolia

Development stage: Unknown
Lead developer: Laboratoire CCD
Modality: Small Molecules
Administration: Oral

Overview

Zytolia is a food for special medical purposes (FSMP) developed by Laboratoire CCD, specifically formulated for the nutritional management of women with polycystic ovary syndrome (PCOS). It contains a combination of myo-inositol (4g), folic acid (vitamin B9, 400µg), vitamin D3 (5µg), zinc (10mg), and chromium (25µg). The primary active component, myo-inositol, acts as an insulin sensitizer, helping to reduce insulin resistance, hyperinsulinism, and hyperandrogenism, while also improving oocyte quality and ovulation. Zytolia is intended for women with PCOS presenting with insulin resistance, hyperandrogenism, or weight issues, and can be used as a complement to ovulation-inducing treatments or IVF protocols.

Brand names: Zytolia

Targets

INSR (Insulin receptor)

Beyond the preview

Go deeper on Zytolia.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Zytolia.

Explore the full profile